3.2 C
New York
Wednesday, February 1, 2023

Is Neoleukin Therapeutics Inc. (NASDAQ: NLTX) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Neoleukin Therapeutics Inc. (NLTX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.0409, or -7.01%, to $0.5429. The Neoleukin Therapeutics Inc. has recorded 919 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Stocks Info

NLTX belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – Specialty & Generic industry. At the end of the last regular session, the stock closed at $0.58 and fluctuated between $0.6400 as its day high and $0.5301 as its day low. The current market capitalization of Neoleukin Therapeutics Inc. is $22.49M. A total of 0.22 million shares were traded on the day, compared to an average of 286.41K shares.

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, NLTX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 2 BUYs and 2 SELLs from insiders. Insiders purchased 15,000 shares during that period but sold 7,193.

In the most recent transaction, Smith Sean Michael sold 1,655 shares of NLTX for 0.99 per share on Aug 10. After the transaction, the Principal Accounting Officer now owns 6,776 company shares. In a previous transaction on May 02, Patel Priti sold 5,538 shares at 1.22 per share. NLTX shares that Chief Medical Officer owns now total 6,462.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for NLTX in the last 3 months, the mean price target is $1.30 with high estimates of $2.00 and low estimates of $0.90. In terms of 52-week highs and lows, NLTX has a high of $3.87 and a low of $0.38.

As of this writing, NLTX has an earnings estimate of -$0.3 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.26 per share and a lower estimate of -$0.34. The company reported an EPS of -$0.28 in the last quarter, which was 6.70% higher than expectations of -$0.3.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 5 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NLTX is Overweight with a score of 2.83. A total of 0 analysts rated the stock as Buy while 0 rated it as Overweight while 5 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles